- Palatin Technologies (NYSE:PTN) finalizes its license deal with AMAG Pharmaceutical (AMAG) for exclusive North American rights to develop and commercialize Rekynda (bremelanotide) for the on-demand treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).
- The company has received an initial payment of $60M under the agreement. Shares are up 20% premarket on increased volume.
Palatin closes Rekynda license deal with AMAG Pharma; shares ahead 20% premarket
Recommended For You
About PTN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PTN | - | - |
Palatin Technologies, Inc. |